Zenyaku Kogyo Teams With Theraclone For Influenza Antibodies
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based Zenyaku Kogyo is hoping Theraclone's I-STAR technology can kick-start the company's influenza vaccine development